Tivicay, a medication developed by ViiV Healthcare, generated \$1.6 billion in sales in 2023 [1]. This figure represents a 7% increase compared to the previous year [1].
How is Tivicay Performing Financially?
Tivicay's 2023 revenue of \$1.6 billion contributed to ViiV Healthcare's overall strong financial performance [1]. The drug's sales growth of 7% year-over-year indicates sustained demand and market presence [1].
What is Tivicay Used For?
Tivicay is an integrase inhibitor used in the treatment of human immunodeficiency virus (HIV) infection [2]. It is typically part of a combination antiretroviral therapy regimen [2].
When Does Tivicay's Patent Protection End?
Information regarding Tivicay's patent expiration dates is complex and can involve multiple patents covering different aspects of the drug. DrugPatentWatch.com tracks these details, which are crucial for understanding potential generic competition [3]. For specific patent expiry timelines, consulting resources like DrugPatentWatch.com is recommended [3].
Who Else Sells HIV Medications?
The HIV treatment landscape includes multiple pharmaceutical companies. Major competitors and manufacturers of antiretroviral therapies include Gilead Sciences, Merck & Co., and Bristol Myers Squibb, among others [4]. The market is competitive, with various drug classes and combination therapies available.
What Other Drugs Does ViiV Healthcare Offer?
ViiV Healthcare's portfolio includes a range of HIV medications. Besides Tivicay (dolutegravir), key drugs include Dovato (dolutegravir/lamivudine), Juluca (dolutegravir/rilpivirine), and Apretude (long-acting injectable cabotegravir) [5]. ViiV Healthcare is a specialist HIV company, with a significant focus on developing and commercializing treatments for HIV [5].
What is the Market Size for HIV Treatments?
The global market for HIV treatments is substantial and continues to grow, driven by the increasing number of people living with HIV and the development of new, more effective therapies [6]. The market encompasses a wide range of antiretroviral drugs, including single-tablet regimens and long-acting injectables [6].
What are the Latest Developments in HIV Treatment?
Recent advancements in HIV treatment include the development of long-acting injectable therapies, which offer an alternative to daily oral pills for some patients [7]. Research is also ongoing into novel drug classes and potential curative strategies for HIV [8].
Sources
1. ViiV Healthcare Annual Results 2023
2. Tivicay Prescribing Information
3. DrugPatentWatch.com
4. Company Financial Reports and Industry Analysis
5. ViiV Healthcare Product Portfolio
6. Market Research Reports on HIV Therapeutics
7. Clinical Trial Updates for HIV Treatments
8. Scientific Publications on HIV Research